AVAnT1A (early COVID-19 vaccination, GPPAD primary prevention)
GPPAD (Global Platform for the Prevention of Autoimmune Diabetes); investigator-initiated, coordinated by Helmholtz Munich
What it is
A randomized GPPAD trial testing whether vaccinating genetically at-risk infants against COVID-19 from 6 months of age lowers the later development of islet autoantibodies or Type 1 diabetes — a primary-prevention bet on the link between early-life viral infection and islet autoimmunity. Investigational only; no efficacy results yet.
Editorial review: .
Most recent recorded citation date: 2025-04-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Delay of onset: No efficacy data exist yet — the trial only began enrolling and its primary outcome (time to islet autoantibodies or T1D) reads out years away — so any delay of progression is entirely unproven.[1]
- Important harms and treatment burden
- Safety: Built on a licensed pediatric COVID-19 vaccine (Comirnaty) with an established safety profile rather than a novel immunosuppressant, an important consideration when intervening in healthy at-risk infants; trial-specific safety is still being collected.[1]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Durability is unknown; whether three early COVID-19 vaccine doses could exert any lasting effect on islet autoimmunity is exactly the unanswered question the trial is built to test.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 10 × 30 + 10 × 20 + 75 × 20 + 30 × 15 + 12 × 15 = 2630; divide by total weight 100. Unrounded weighted result: 26.3.
No efficacy data exist yet — the trial only began enrolling and its primary outcome (time to islet autoantibodies or T1D) reads out years away — so any delay of progression is entirely unproven.[1]
Durability is unknown; whether three early COVID-19 vaccine doses could exert any lasting effect on islet autoimmunity is exactly the unanswered question the trial is built to test.[1]
Built on a licensed pediatric COVID-19 vaccine (Comirnaty) with an established safety profile rather than a novel immunosuppressant, an important consideration when intervening in healthy at-risk infants; trial-specific safety is still being collected.[1]
Aimed at the earliest possible point — genetically at-risk infants before any autoimmunity (primary prevention) — so it targets a single narrow window rather than a breadth of disease stages.[1]
Available only inside the trial at GPPAD sites in Germany, Belgium, Sweden, the UK, and Italy; there is no approved preventive indication, though the vaccine itself is already widely licensed.[2]
The full picture
AVAnT1A is a Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) primary-prevention trial: it tests whether vaccinating genetically at-risk babies against COVID-19 can reduce the later emergence of islet autoimmunity. The premise is epidemiological — viral infections in the first year of life have been linked to a higher risk of islet autoantibodies and Type 1 diabetes (T1D) — so the hypothesis is that blunting one such viral hit early might lower that risk.
The trial screens newborns in Germany, Belgium, Sweden, the UK, and Italy and enrolls those with greater than a 10% expected risk of islet autoantibodies by age 6, judged by HLA genotype, a polygenic risk score, and family history. About 2,252 infants are enrolled at 3-4 months and randomized 1:1 from 6 months to receive three doses of a licensed pediatric COVID-19 vaccine (Comirnaty) starting at 6 months, or saline placebo, then followed with intensive infection surveillance. The primary outcome is time to persistent confirmed islet autoantibodies or a T1D diagnosis.
This is genuinely investigational: no efficacy data exist, and the design follows children to a maximum age of 6, so a verdict is years away. Its appeal is that it intervenes before autoimmunity starts using an already-licensed vaccine rather than an immunosuppressant.
Coming soon
ETA · Primary-outcome results not expected until roughly the end of the decade (children followed to a minimum age of 2.5 and maximum of 6 years).
- →Completion of enrollment of ~2,252 genetically at-risk infants and intensive viral-infection surveillance across GPPAD sites in Germany, Belgium, Sweden, and the UK
Sources
- [1]Anti-viral action against type 1 diabetes autoimmunity: The GPPAD-AVAnT1A study protocol · Peer-reviewed study · 2025-04-01
- [2]Anti-Viral Action Against Type 1 Diabetes Autoimmunity (AVAnT1A) · Trial registry · 2024-06-11